Published • loading... • Updated
Cellares adds ARK backing for cell therapy scale-up
Summary by Industrial News
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Cellares adds ARK backing for cell therapy scale-up
Cellares has added ARK Invest to its Series D financing, with a $20 million investment that lifts the round to $277 million and strengthens backing for automated cell therapy manufacturing. The investment joins existing backers including BlackRock, Eclipse, T. Rowe Price Investment Management, Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global Ventures, DFJ Growth, and Willett Advisors. Cellares is using…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
